Dermata Therapeutics (DRMA) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $0.86, -5.49% vs the prior close of $0.91.
- Volume 2.49M shares, 0.6x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
DRMA slides 5.5% to $0.86. Closed at $0.86, -5.49% vs the prior close of $0.91. Day range $0.81–$0.95, opened at $0.90.
DRMA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — DRMA slides 5.5% to $0.86
- Closed at $0.86, -5.49% vs the prior close of $0.91. Day range $0.81–$0.95, opened at $0.90.
- Volume was 2.49M shares, 0.6x its 50-day average of 4.30M — lighter than usual.
- Price is -28.9% vs its 50-day average ($1.21) and -37.8% vs its 200-day average ($1.38).
- 52-week range $0.60–$4.66; today's close sits at 6% of that range, 81.5% below the 52-week high.
Oct 15, 2026 — DRMA jumps 37.3% to $0.91 on 190.5x normal volume
- Closed at $0.91, +37.25% vs the prior close of $0.66. Day range $0.77–$1.18, opened at $0.77.
- Volume was 169.97M shares, 190.5x its 50-day average of 892.12K — unusually heavy trading.
- Price is -25.1% vs its 50-day average ($1.21) and -34.5% vs its 200-day average ($1.39).
- 52-week range $0.60–$4.66; today's close sits at 8% of that range, 80.5% below the 52-week high.
Oct 14, 2026 — DRMA slides 22.9% to $0.66, a 52-week low, 6 down days in a row
- Closed at $0.66, -22.91% vs the prior close of $0.86. Day range $0.60–$0.86, opened at $0.86.
- Volume was 350.80K shares, 0.4x its 50-day average of 886.05K — lighter than usual.
- Price is -45.6% vs its 50-day average ($1.22) and -52.5% vs its 200-day average ($1.39).
- 52-week range $0.60–$4.66; today's close sits at 1% of that range, 85.8% below the 52-week high.
- That makes 6 straight losses.
Oct 13, 2026 — DRMA slides 3.4% to $0.86, a 52-week low, 5 down days in a row
- Closed at $0.86, -3.37% vs the prior close of $0.89. Day range $0.84–$0.90, opened at $0.89.
- Volume was 38.10K shares, 0.0x its 50-day average of 889.70K — lighter than usual.
- Price is -30.0% vs its 50-day average ($1.23) and -38.6% vs its 200-day average ($1.40).
- 52-week range $0.84–$4.66; today's close sits at 1% of that range, 81.5% below the 52-week high.
- That makes 5 straight losses.
Oct 12, 2026 — DRMA slides 12.7% to $0.89, a 52-week low, 4 down days in a row
- Closed at $0.89, -12.75% vs the prior close of $1.02. Day range $0.89–$1.01, opened at $1.00.
- Volume was 39.60K shares, 0.0x its 50-day average of 890.58K — lighter than usual.
- Price is -27.8% vs its 50-day average ($1.23) and -36.8% vs its 200-day average ($1.41).
- 52-week range $0.89–$4.66; today's close sits at 0% of that range, 80.9% below the 52-week high.
- That makes 4 straight losses.
Oct 9, 2026 — DRMA slides 4.7% to $1.02, a 52-week low, 3 down days in a row
- Closed at $1.02, -4.67% vs the prior close of $1.07. Day range $1.01–$1.08, opened at $1.08.
- Volume was 22.10K shares, 0.0x its 50-day average of 891.05K — lighter than usual.
- Price is -17.6% vs its 50-day average ($1.24) and -27.9% vs its 200-day average ($1.41).
- 52-week range $0.95–$4.84; today's close sits at 2% of that range, 78.9% below the 52-week high.
- That makes 3 straight losses.
- SEC filings that day: S-3.
Oct 8, 2026 — DRMA slides 4.5% to $1.07, a 52-week low
- Closed at $1.07, -4.46% vs the prior close of $1.12. Day range $1.05–$1.10, opened at $1.10.
- Volume was 7.00K shares, 0.0x its 50-day average of 892.64K — lighter than usual.
- Price is -13.8% vs its 50-day average ($1.24) and -24.6% vs its 200-day average ($1.42).
- 52-week range $0.95–$5.18; today's close sits at 3% of that range, 79.3% below the 52-week high.
Oct 7, 2026 — DRMA dips 0.9% to $1.12
- Closed at $1.12, -0.88% vs the prior close of $1.13. Day range $1.11–$1.14, opened at $1.14.
- Volume was 7.40K shares, 0.0x its 50-day average of 893.61K — lighter than usual.
- Price is -9.9% vs its 50-day average ($1.24) and -21.4% vs its 200-day average ($1.43).
- 52-week range $0.95–$5.18; today's close sits at 4% of that range, 78.4% below the 52-week high.
Oct 6, 2026 — DRMA rises 1.8% to $1.13
- Closed at $1.13, +1.80% vs the prior close of $1.11. Day range $1.11–$1.14, opened at $1.12.
- Volume was 29.60K shares, 0.0x its 50-day average of 893.87K — lighter than usual.
- Price is -9.3% vs its 50-day average ($1.25) and -21.0% vs its 200-day average ($1.43).
- 52-week range $0.95–$5.87; today's close sits at 4% of that range, 80.7% below the 52-week high.
Oct 5, 2026 — DRMA rises 0.5% to $1.11
- Closed at $1.11, +0.45% vs the prior close of $1.11. Day range $1.09–$1.16, opened at $1.16.
- Volume was 14.10K shares, 0.0x its 50-day average of 895.25K — lighter than usual.
- Price is -11.1% vs its 50-day average ($1.25) and -22.7% vs its 200-day average ($1.44).
- 52-week range $0.95–$5.87; today's close sits at 3% of that range, 81.1% below the 52-week high.
Oct 2, 2026 — DRMA dips 0.5% to $1.11
- Closed at $1.11, -0.45% vs the prior close of $1.11. Day range $1.08–$1.16, opened at $1.16.
- Volume was 17.60K shares, 0.0x its 50-day average of 895.26K — lighter than usual.
- Price is -11.8% vs its 50-day average ($1.25) and -23.4% vs its 200-day average ($1.44).
- 52-week range $0.95–$5.87; today's close sits at 3% of that range, 81.2% below the 52-week high.
DRMA latest news & SEC filings
Every SEC filing by or about DRMA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 9, 2026 · Form S-3 — Shelf registration (S-3)
Shelf registration (S-3) — lets the company sell securities over time
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 17, 2026 · Form 25-NSE — Notice that a security is being removed from exchange listing
Notice that a security is being removed from exchange listing
Aug 17, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 3.02 — Sold unregistered shares.
- Item 8.01 — Reported other events the company considers important.
Aug 11, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$2.97M (prior year -$1.70M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.74 (prior year -$1.66) (loss narrowed vs Jun 30, 2025)
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade DRMA
- Last results release: Aug 11, 2026 (8-K Item 2.02). Previous ones: May 13, 2026, Mar 26, 2026, Nov 14, 2025. Based on that rhythm, the next report is likely around Nov 10, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 5.56% (largest 37.3%). That is a volatile stock.
- Liquidity: about 8.69M shares (≈$7.47M) trade per day on average.
- 52-week position: $0.86 vs a range of $0.60–$4.66 (6% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:10 on Aug 1, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 4 open-market buys, 4 sales; latest: Kathleen D. Scott sold 11 shares on Jun 16, 2026.
- Latest filings: 8-K Aug 17, 2026; 10-Q Aug 11, 2026; 8-K Aug 11, 2026.
- Share count: 4.02M shares outstanding (Aug 10, 2026), +490.1% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
DRMA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 0.90 | 0.95 | 0.81 | 0.86 | 2.49M |
| Oct 15, 2026 | 0.77 | 1.18 | 0.77 | 0.91 | 170.52M |
| Oct 14, 2026 | 0.86 | 0.86 | 0.60 | 0.66 | 350.80K |
| Oct 13, 2026 | 0.89 | 0.90 | 0.84 | 0.86 | 38.10K |
| Oct 12, 2026 | 1.00 | 1.01 | 0.89 | 0.89 | 39.60K |
| Oct 9, 2026 | 1.08 | 1.08 | 1.01 | 1.02 | 22.10K |
| Oct 8, 2026 | 1.10 | 1.10 | 1.05 | 1.07 | 7.00K |
| Oct 7, 2026 | 1.14 | 1.14 | 1.11 | 1.12 | 7.40K |
| Oct 6, 2026 | 1.12 | 1.14 | 1.11 | 1.13 | 29.60K |
| Oct 5, 2026 | 1.16 | 1.16 | 1.09 | 1.11 | 14.10K |
| Oct 2, 2026 | 1.16 | 1.16 | 1.08 | 1.11 | 17.60K |
| Oct 1, 2026 | 1.08 | 1.13 | 1.06 | 1.11 | 20.80K |
| Sep 30, 2026 | 1.10 | 1.12 | 1.10 | 1.10 | 14.70K |
| Sep 29, 2026 | 1.12 | 1.17 | 1.12 | 1.13 | 10.40K |
| Sep 28, 2026 | 1.14 | 1.16 | 1.10 | 1.12 | 25.00K |
| Sep 25, 2026 | 1.15 | 1.20 | 1.13 | 1.14 | 30.30K |
| Sep 24, 2026 | 1.15 | 1.25 | 1.12 | 1.17 | 78.10K |
| Sep 23, 2026 | 1.18 | 1.18 | 1.12 | 1.12 | 14.40K |
| Sep 22, 2026 | 1.17 | 1.19 | 1.15 | 1.15 | 25.80K |
| Sep 21, 2026 | 1.15 | 1.18 | 1.14 | 1.15 | 19.70K |
About Dermata Therapeutics
Dermata Therapeutics (DRMA) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SAN DIEGO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1853816.
DRMA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Brittany Bradrick | Director | Jan 6, 2026 |
| Mary Fisher | Director | Jan 6, 2026 |
| David F Hale | Director | Jan 6, 2026 |
| Steven J Mento | Director | Jan 6, 2026 |
| Gerald T Proehl | PRESIDENT, CHAIRMAN, CEO | Aug 18, 2026 |
| Andrew Seth Sandler | Director | Jan 6, 2026 |
| Kathleen D. Scott | Director | Jun 16, 2026 |
| Wendell Wierenga | Director | Jan 6, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Munera Maria E Bedoya-Toro | SVP, Regulatory Affairs | Mar 17, 2026 |
| Christopher J. Nardo | Senior VP, CDO | Jan 6, 2026 |
| Gerald T Proehl | PRESIDENT, CHAIRMAN, CEO | Aug 18, 2026 |
| Hoose Kyri K. Van | SVP, CFO | Aug 18, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 16, 2026 | Kathleen D. Scott | Sale | 11 | $1.19 |
| Jun 16, 2026 | Kathleen D. Scott | Sale | 11 | $1.19 |
| Jun 16, 2026 | Kathleen D. Scott | Sale | 11 | $1.19 |
| Jun 16, 2026 | Kathleen D. Scott | Sale | 11 | $1.19 |
| Feb 17, 2026 | Munera Maria E Bedoya-Toro | Buy | 1,000 | $1.27 |
| Feb 17, 2026 | Munera Maria E Bedoya-Toro | Buy | 1,000 | $1.27 |
| Feb 17, 2026 | Munera Maria E Bedoya-Toro | Buy | 1,000 | $1.27 |
| Feb 17, 2026 | Munera Maria E Bedoya-Toro | Buy | 1,000 | $1.27 |
DRMA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-7.56M | -8.16 | $-7.76M |
| Dec 31, 2024 | — | $-12.29M | -80.32 | $-11.16M |
| Dec 31, 2023 | — | $-7.79M | -39.99 | $-6.41M |
| Dec 31, 2022 | — | $-9.61M | — | $-8.83M |
| Dec 31, 2021 | — | $-7.90M | — | $-5.69M |
Latest balance sheet: total assets $5.32M, total liabilities $1.83M, cash $4.41M (as of Jun 30, 2026).
DRMA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 11, 2026 | 8-K Item 2.02 (results) | $1.08 |
| May 13, 2026 | 8-K Item 2.02 (results) | $1.19 |
| Mar 26, 2026 | 8-K Item 2.02 (results) | $1.37 |
| Nov 14, 2025 | 8-K Item 2.02 (results) | $3.07 |
| Aug 13, 2025 | 8-K Item 2.02 (results) | $6.45 |
| May 14, 2025 | 8-K Item 2.02 (results) | $7.79 |
| Mar 17, 2025 | 8-K Item 2.02 (results) | $11.70 |
| Nov 14, 2024 | 8-K Item 2.02 (results) | $11.89 |
| Aug 7, 2024 | 8-K Item 2.02 (results) | — |
| May 15, 2024 | 8-K Item 2.02 (results) | — |
| Mar 21, 2024 | 8-K Item 2.02 (results) | — |
| Nov 9, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on DRMA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.